- Fee assured
- Verified this account
Dr Bertelli is a Consultant Medical Oncologist at the Sussex Cancer Centre in Brighton. He trained in Genoa, Italy, where he qualified as MD in 1986. He started his career at Genoa’s National Cancer Institute, and also worked at the Santa Croce Hospital in Cuneo (Piedmont). In 2002 he moved to Swansea, UK, where he worked as a Consultant and Honorary Senior Lecturer until February 2018. He has served as Research Lead for the South West Wales Cancer Centre and as a member of the NCRI Breast Cancer Studies Group.
His main clinical and research interest is the treatment of early and advanced breast cancer with chemotherapy, hormone therapy and targeted agents. He has contributed to several national and international clinical trials as Principal Investigator, Chief Investigator or Steering Committee Member. He is the Author or co-Author of more than 100 publications and in 2007 he was awarded a PhD from the University of Maastricht for his research in the field of endocrine treatment of breast cancer.
Areas of interest
Breast cancer; chemotherapy; hormone therapy; targeted treatments
Current NHS consultant posts held
Consultant Medical Oncologist, Brighton and Sussex University Hospitals NHS Trust, Brighton.
Honorary Clinical Reader, Brighton and Sussex Medical School.
Principal Investigator in multicentre clinical trials for breast cancer. Member of the National cancer Research Institute Advanced Breast Cancer Trials subgroup.
Walking, cycling, classic music and literature.
(Additional) Languages spoken
- Italian - Native or bilingual
- French - Basic
- Spanish - Basic
Lambertini M, Moore HCF, Leonard RCF, Loibl S, Munster P, Bruzzone M, Boni L, Unger JM, Anderson RA, Mehta K, Minton S, Poggio F, Albain KS, Adamson DJA, Gerber B, Cripps A, Bertelli G, Seiler S, Ceppi M, Partridge AH, Del Mastro L.
Gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: a systematic review and meta-analysis of individual patient-level data.
Journal of Clinical Oncology 2018;36:1981-1990
Brown J, Rathbone E, Hinsley S, Gregory W, Gossiel F, Marshall H, Burkinshaw R, Shulver H, Thandar H, Bertelli G, Maccon K, Bowman A, Hanby A, Bell R, Cameron D, Coleman R.
Associations Between Serum Bone Biomarkers in Early Breast Cancer and Development of Bone Metastasis: Results From the AZURE (BIG01/04) Trial.
Journal of the National Cancer Institute 2018;110:871-879
Cameron D, Morden JP, Canney P, Velikova G, Coleman R, Bartlett J, Agrawal R, Banerji J, Bertelli G, Bloomfield D, Brunt AM, Earl H, Ellis P, Gaunt C, Gillman A, Hearfield N, Laing R, Murray N, Couper N, Stein RC, Verrill M, Wardley A, Barrett-Lee P, Bliss JM; TACT2 Investigators.
Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial.
Lancet Oncology 2017;18:929-945
Leonard R, Adamson D, Bertelli G, Mansi J, Yellowlees A, Dunlop J, Thomas GA, Coleman RE, Anderson RA; Anglo Celtic Collaborative Oncology Group and National Cancer Research Institute trialists.
GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: the Anglo Celtic Group OPTION trial.
Annals of Oncology 2017;28;1811-1816
Morden JP, Alvarez I, Bertelli G, Coates AS, Coleman R, Fallowfield L, Jassem J, Jones S, Kilburn L, Lønning PE, Ortmann O, Snowdon C, van de Velde C, Andersen J, Del Mastro L, Dodwell D, Holmberg S, Nicholas H, Paridaens R, Bliss JM,Coombes RC.
Long-Term Follow-Up of the Intergroup Exemestane Study.
Journal of Clinical Oncology 2017;35:2507-2514
- MD University of Genoa, Italy 1986
- PhD University of Maastricht, The Netherlands 2007
- FRCP (Edin) Royal College of Physicians, Edinburgh 2003
Reference number 6057041
Details of entry to specialist register
- Medical Oncology , 2003
Affiliations / memberships
ASCO (American Society of Clinical Oncology)
ESMO (European Society of Medical Oncology)
ACP (Association of Cancer Physicians)
ACCOG (Anglo-Celtic Co-operative Oncology Group)
Post treatment communication
Following treatment of a Bupa member, I will communicate with GPs in line with Department of Health, GMC and appropriate professional bodies guidelines.